Drug intelligence / Profile preview

N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is classified as an aromatic anilide and is a small molecule. It has been studied for its potential biological activities, including interactions with vascular endothelial growth factor receptor 2 (VEGFR2) and the angiopoietin-1 receptor (TIE2). However, specific details about its mechanism of action or clinical use are not widely available.

Other names: N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamideCHEMBL385178CHEMBL-385178CHEMBL 385178PD005650PD-005650PD 005650

Targets

TEK (Tie2)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide.